Dynavax Technologies said safety data show no difference in terms of autoimmune adverse events between those who got its hepatitis B vaccine candidate Heplisav and GlaxoSmithKline's recently approved Engerix-B. Dynavax said the study was intended for submission to the FDA in relation to a clinical hold that was lifted in September.

Full Story:

Related Summaries